ID   PDC6I_HUMAN             Reviewed;         868 AA.
AC   Q8WUM4; C5MQH7; E9PFU1; Q6NUS1; Q9BX86; Q9NUN0; Q9P2H2; Q9UKL5;
DT   23-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   22-JUL-2015, entry version 144.
DE   RecName: Full=Programmed cell death 6-interacting protein;
DE            Short=PDCD6-interacting protein;
DE   AltName: Full=ALG-2-interacting protein 1;
DE   AltName: Full=ALG-2-interacting protein X;
DE   AltName: Full=Hp95;
GN   Name=PDCD6IP; Synonyms=AIP1, ALIX, KIAA1375;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-550.
RX   PubMed=11683497; DOI=10.1046/j.1432-0436.2001.670406.x;
RA   Wu Y., Pan S., Che S., He G., Nelman-Gonzalez M., Weil M.M., Kuang J.;
RT   "Overexpression of Hp95 induces G1 phase arrest in confluent HeLa
RT   cells.";
RL   Differentiation 67:139-153(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=19906316; DOI=10.1186/1471-2164-10-518;
RA   Wang P., Yu P., Gao P., Shi T., Ma D.;
RT   "Discovery of novel human transcript variants by analysis of intronic
RT   single-block EST with polyadenylation site.";
RL   BMC Genomics 10:518-518(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-309 AND
RP   LEU-730.
RA   Li H., Shioda T., Isselbacher K.J.;
RT   "Molecular cloning of human ALG-2 interacting protein 1 (AIP1).";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS MET-7 AND ILE-378.
RC   TISSUE=Lymph, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-23; 111-120; 216-229; 439-446; 457-469 AND
RP   542-553, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Osteosarcoma;
RA   Bienvenut W.V., Glen H., Frame M.C.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 209-868 (ISOFORM 1), AND
RP   VARIANT ILE-378.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 323-868 (ISOFORM 1), AND
RP   VARIANT SER-550.
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [10]
RP   INTERACTION WITH CHMP4A AND CHMP4B.
RX   PubMed=12860994; DOI=10.1074/jbc.M301604200;
RA   Katoh K., Shibata H., Suzuki H., Narai A., Ishidoh K., Kominami E.,
RA   Yoshimori T., Maki M.;
RT   "The ALG-2-interacting protein Alix associates with CHMP4b, a human
RT   homologue of yeast Snf7 that is involved in multivesicular body
RT   sorting.";
RL   J. Biol. Chem. 278:39104-39113(2003).
RN   [11]
RP   FUNCTION IN HIV-1 BUDDING, AND INTERACTION WITH CHMP4A; CHMP4B;
RP   CHMP4C; HIV-1 P6 AND EIAV P9.
RX   PubMed=14505569; DOI=10.1016/S0092-8674(03)00653-6;
RA   Strack B., Calistri A., Craig S., Popova E., Goettlinger H.G.;
RT   "AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning
RT   in virus budding.";
RL   Cell 114:689-699(2003).
RN   [12]
RP   FUNCTION IN HIV-1 BUDDING, SELF-ASSOCIATION, INTERACTION WITH TSG101;
RP   CHMP4A; CHMP4B CHMP4C, AND SUBCELLULAR LOCATION.
RX   PubMed=14505570; DOI=10.1016/S0092-8674(03)00714-1;
RA   von Schwedler U.K., Stuchell M., Mueller B., Ward D.M., Chung H.-Y.,
RA   Morita E., Wang H.E., Davis T., He G.P., Cimbora D.M., Scott A.,
RA   Kraeusslich H.-G., Kaplan J., Morham S.G., Sundquist W.I.;
RT   "The protein network of HIV budding.";
RL   Cell 114:701-713(2003).
RN   [13]
RP   SELF-ASSOCIATION, AND INTERACTION WITH TSG101; CHMP4A; CHMP4B; CHMP4C
RP   AND EIAV P9.
RX   PubMed=14519844; DOI=10.1073/pnas.2133846100;
RA   Martin-Serrano J., Yarovoy A., Perez-Caballero D., Bieniasz P.D.;
RT   "Divergent retroviral late-budding domains recruit vacuolar protein
RT   sorting factors by using alternative adaptor proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12414-12419(2003).
RN   [14]
RP   ERRATUM.
RA   Martin-Serrano J., Yarovoy A., Perez-Caballero D., Bieniasz P.D.;
RL   Proc. Natl. Acad. Sci. U.S.A. 100:152845-152845(2003).
RN   [15]
RP   INTERACTION WITH CHMP4A; CHMP4B AND CHMP4C.
RX   PubMed=14678797; DOI=10.1016/j.abb.2003.09.038;
RA   Katoh K., Shibata H., Hatta K., Maki M.;
RT   "CHMP4b is a major binding partner of the ALG-2-interacting protein
RT   Alix among the three CHMP4 isoforms.";
RL   Arch. Biochem. Biophys. 421:159-165(2004).
RN   [16]
RP   INTERACTION WITH CHMP4A; CHMP4B AND CHMP4C.
RX   PubMed=14583093; DOI=10.1042/BJ20031347;
RA   Peck J.W., Bowden E.T., Burbelo P.D.;
RT   "Structure and function of human Vps20 and Snf7 proteins.";
RL   Biochem. J. 377:693-700(2004).
RN   [17]
RP   FUNCTION IN ENDOSOME ORGANIZATION.
RX   PubMed=14739459; DOI=10.1126/science.1092425;
RA   Matsuo H., Chevallier J., Mayran N., Le Blanc I., Ferguson C.,
RA   Faure J., Blanc N.S., Matile S., Dubochet J., Sadoul R., Parton R.G.,
RA   Vilbois F., Gruenberg J.;
RT   "Role of LBPA and Alix in multivesicular liposome formation and
RT   endosome organization.";
RL   Science 303:531-534(2004).
RN   [18]
RP   INTERACTION WITH SGSM3, AND SUBCELLULAR LOCATION.
RX   PubMed=15849434; DOI=10.1271/bbb.69.861;
RA   Ichioka F., Horii M., Katoh K., Terasawa Y., Shibata H., Maki M.;
RT   "Identification of Rab GTPase-activating protein-like protein
RT   (RabGAPLP) as a novel Alix/AIP1-interacting protein.";
RL   Biosci. Biotechnol. Biochem. 69:861-865(2005).
RN   [19]
RP   INTERACTION WITH MURINE LEUKEMIA VIRUS GAG POLYPROTEIN.
RX   PubMed=15908698; DOI=10.1074/jbc.M413735200;
RA   Segura-Morales C., Pescia C., Chatellard-Causse C., Sadoul R.,
RA   Bertrand E., Basyuk E.;
RT   "Tsg101 and Alix interact with murine leukemia virus Gag and cooperate
RT   with Nedd4 ubiquitin ligases during budding.";
RL   J. Biol. Chem. 280:27004-27012(2005).
RN   [20]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH PDCD6.
RX   PubMed=16957052; DOI=10.1091/mbc.E06-05-0444;
RA   Yamasaki A., Tani K., Yamamoto A., Kitamura N., Komada M.;
RT   "The Ca2+-binding protein ALG-2 is recruited to endoplasmic reticulum
RT   exit sites by Sec31A and stabilizes the localization of Sec31A.";
RL   Mol. Biol. Cell 17:4876-4887(2006).
RN   [22]
RP   FUNCTION IN CYTOKINESIS, SUBCELLULAR LOCATION, INTERACTION WITH CEP55
RP   AND CD2AP, AND MUTAGENESIS OF ILE-212; PHE-676 AND 800-GLY--PRO-802.
RX   PubMed=17853893; DOI=10.1038/sj.emboj.7601850;
RA   Morita E., Sandrin V., Chung H.Y., Morham S.G., Gygi S.P.,
RA   Rodesch C.K., Sundquist W.I.;
RT   "Human ESCRT and ALIX proteins interact with proteins of the midbody
RT   and function in cytokinesis.";
RL   EMBO J. 26:4215-4227(2007).
RN   [23]
RP   FUNCTION IN HIV-1 BUDDING, INTERACTION WITH CHMP4B, AND MUTAGENESIS OF
RP   PHE-199; LEU-216; PHE-317; ILE-318 AND TYR-319.
RX   PubMed=17428861; DOI=10.1128/JVI.00314-07;
RA   Usami Y., Popov S., Goettlinger H.G.;
RT   "Potent rescue of human immunodeficiency virus type 1 late domain
RT   mutants by ALIX/AIP1 depends on its CHMP4 binding site.";
RL   J. Virol. 81:6614-6622(2007).
RN   [24]
RP   FUNCTION IN CYTOKINESIS, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   CEP55.
RX   PubMed=17556548; DOI=10.1126/science.1143422;
RA   Carlton J.G., Martin-Serrano J.;
RT   "Parallels between cytokinesis and retroviral budding: a role for the
RT   ESCRT machinery.";
RL   Science 316:1908-1912(2007).
RN   [25]
RP   INTERACTION WITH PDCD6.
RX   PubMed=18256029; DOI=10.1074/jbc.M800717200;
RA   Shibata H., Suzuki H., Kakiuchi T., Inuzuka T., Yoshida H., Mizuno T.,
RA   Maki M.;
RT   "Identification of Alix-type and non-Alix-type ALG-2-binding sites in
RT   human phospholipid scramblase 3: differential binding to an
RT   alternatively spliced isoform and amino acid-substituted mutants.";
RL   J. Biol. Chem. 283:9623-9632(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-730; THR-738 AND
RP   THR-741, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   INTERACTION WITH TSG101.
RX   PubMed=19520058; DOI=10.1016/j.bbrc.2009.06.015;
RA   Okumura M., Ichioka F., Kobayashi R., Suzuki H., Yoshida H.,
RA   Shibata H., Maki M.;
RT   "Penta-EF-hand protein ALG-2 functions as a Ca2+-dependent adaptor
RT   that bridges Alix and TSG101.";
RL   Biochem. Biophys. Res. Commun. 386:237-241(2009).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-215, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [30]
RP   PHOSPHORYLATION, AND INTERACTION WITH PDGFRB.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-738 AND THR-741, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [33]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 1-698, INTERACTION WITH
RP   CHMP4A; HIV-1 P6; EIAV P9; TSG101; SH3GL1 AND SH3GL2, AND MUTAGENESIS
RP   OF ILE-212; TYR-319; PHE-495; VAL-498; VAL-509; PHE-676; LEU-680;
RP   ILE-683; PRO-720 AND 757-ARG-PRO-758.
RX   PubMed=17350572; DOI=10.1016/j.cell.2007.01.035;
RA   Fisher R.D., Chung H.Y., Zhai Q., Robinson H., Sundquist W.I.,
RA   Hill C.P.;
RT   "Structural and biochemical studies of ALIX/AIP1 and its role in
RT   retrovirus budding.";
RL   Cell 128:841-852(2007).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.87 ANGSTROMS) OF 360-702, INTERACTION WITH
RP   HIV-1 P6, AND MUTAGENESIS OF VAL-498; VAL-509; CYS-512; PHE-676 AND
RP   ILE-683.
RX   PubMed=17277784; DOI=10.1038/nsmb1203;
RA   Lee S., Joshi A., Nagashima K., Freed E.O., Hurley J.H.;
RT   "Structural basis for viral late-domain binding to Alix.";
RL   Nat. Struct. Mol. Biol. 14:194-199(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 2-698 IN COMPLEX WITH HIV-1
RP   P6, X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 2-698 IN COMPLEX WITH
RP   HIV-1 P9, AND INTERACTION WITH EIAV P9.
RX   PubMed=18066081; DOI=10.1038/nsmb1319;
RA   Zhai Q., Fisher R.D., Chung H.Y., Myszka D.G., Sundquist W.I.,
RA   Hill C.P.;
RT   "Structural and functional studies of ALIX interactions with YPX(n)L
RT   late domains of HIV-1 and EIAV.";
RL   Nat. Struct. Mol. Biol. 15:43-49(2008).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 1-359 IN COMPLEX WITH
RP   CHMP4A, X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-359 IN COMPLEX WITH
RP   CHMP4B, AND X-RAY CRYSTALLOGRAPHY (2.02 ANGSTROMS) OF 1-359 IN COMPLEX
RP   WITH CHMP4C.
RX   PubMed=18511562; DOI=10.1073/pnas.0801567105;
RA   McCullough J., Fisher R.D., Whitby F.G., Sundquist W.I., Hill C.P.;
RT   "ALIX-CHMP4 interactions in the human ESCRT pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:7687-7691(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 797-809 IN COMPLEX WITH
RP   CEP55, AND MUTAGENESIS OF PRO-801; PRO-802 AND TYR-806.
RX   PubMed=18948538; DOI=10.1126/science.1162042;
RA   Lee H.H., Elia N., Ghirlando R., Lippincott-Schwartz J., Hurley J.H.;
RT   "Midbody targeting of the ESCRT machinery by a noncanonical coiled
RT   coil in CEP55.";
RL   Science 322:576-580(2008).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 799-812 IN COMPLEX WITH
RP   PDCD6.
RX   PubMed=18940611; DOI=10.1016/j.str.2008.07.012;
RA   Suzuki H., Kawasaki M., Inuzuka T., Okumura M., Kakiuchi T.,
RA   Shibata H., Wakatsuki S., Maki M.;
RT   "Structural basis for Ca2+ -dependent formation of ALG-2/Alix peptide
RT   complex: Ca2+/EF3-driven arginine switch mechanism.";
RL   Structure 16:1562-1573(2008).
RN   [41]
RP   VARIANT SER-429.
RX   PubMed=22073189; DOI=10.1371/journal.pone.0026741;
RA   Benitez B.A., Alvarado D., Cai Y., Mayo K., Chakraverty S., Norton J.,
RA   Morris J.C., Sands M.S., Goate A., Cruchaga C.;
RT   "Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal
RT   ceroid-lipofuscinosis.";
RL   PLoS ONE 6:E26741-E26741(2011).
CC   -!- FUNCTION: Class E VPS protein involved in concentration and
CC       sorting of cargo proteins of the multivesicular body (MVB) for
CC       incorporation into intralumenal vesicles (ILVs) that are generated
CC       by invagination and scission from the limiting membrane of the
CC       endosome. Binds to the phospholipid lysobisphosphatidic acid
CC       (LBPA) which is abundant in MVBs internal membranes. The MVB
CC       pathway appears to require the sequential function of ESCRT-O,
CC       -I,-II and -III complexes. The ESCRT machinery also functions in
CC       topologically equivalent membrane fission events, such as the
CC       terminal stages of cytokinesis and enveloped virus budding (HIV-1
CC       and other lentiviruses). Appears to be an adapter for a subset of
CC       ESCRT-III proteins, such as CHMP4, to function at distinct
CC       membranes. Required for completion of cytokinesis. Involved in
CC       HIV-1 virus budding. Can replace TSG101 it its role of supporting
CC       HIV-1 release; this function implies the interaction with CHMP4B.
CC       May play a role in the regulation of both apoptosis and cell
CC       proliferation. {ECO:0000269|PubMed:14505569,
CC       ECO:0000269|PubMed:14505570, ECO:0000269|PubMed:14739459,
CC       ECO:0000269|PubMed:17428861, ECO:0000269|PubMed:17556548,
CC       ECO:0000269|PubMed:17853893}.
CC   -!- SUBUNIT: Interacts with SH3KBP1. Interacts with PDCD6 and TSG101
CC       in a calcium-dependent manner. Interacts with and SGSM3. Self-
CC       associates. Interacts with CHMP4A; the interaction is direct.
CC       Interacts with CHMP4B; the interaction is direct. Interacts with
CC       CHMP4C; the interaction is direct. Interacts with HIV-1 p6.
CC       Interacts with EIAV p9; the interaction has been shown in vitro.
CC       Interacts with CEP55; the interaction is direct; CEP55 binds
CC       PDCD6IP in a 2:1 stoechiometry. May interact with PDGFRB.
CC       Interacts with SH3GL1 and SH3GL2. Interacts with murine leukemia
CC       virus Gag polyprotein (via LYPX(n)L motif). Interacts with murine
CC       leukemia virus Gag polyprotein (via LYPX(n)L motif).
CC       {ECO:0000269|PubMed:12860994, ECO:0000269|PubMed:14505569,
CC       ECO:0000269|PubMed:14505570, ECO:0000269|PubMed:14519844,
CC       ECO:0000269|PubMed:14583093, ECO:0000269|PubMed:14678797,
CC       ECO:0000269|PubMed:15849434, ECO:0000269|PubMed:15908698,
CC       ECO:0000269|PubMed:16957052, ECO:0000269|PubMed:17277784,
CC       ECO:0000269|PubMed:17350572, ECO:0000269|PubMed:17428861,
CC       ECO:0000269|PubMed:17556548, ECO:0000269|PubMed:17853893,
CC       ECO:0000269|PubMed:18066081, ECO:0000269|PubMed:18256029,
CC       ECO:0000269|PubMed:18511562, ECO:0000269|PubMed:18940611,
CC       ECO:0000269|PubMed:18948538, ECO:0000269|PubMed:19520058,
CC       ECO:0000269|PubMed:20494825}.
CC   -!- INTERACTION:
CC       P29991:- (xeno); NbExp=3; IntAct=EBI-310624, EBI-8826747;
CC       Q9Y5K6:CD2AP; NbExp=2; IntAct=EBI-310624, EBI-298152;
CC       D3DR37:CEP55; NbExp=3; IntAct=EBI-310624, EBI-10173536;
CC       Q53EZ4:CEP55; NbExp=9; IntAct=EBI-310624, EBI-747776;
CC       P06241:FYN; NbExp=6; IntAct=EBI-310624, EBI-515315;
CC       P03347:gag (xeno); NbExp=2; IntAct=EBI-310624, EBI-1220741;
CC       P69730:gag (xeno); NbExp=2; IntAct=EBI-310624, EBI-1220941;
CC       P08631:HCK; NbExp=4; IntAct=EBI-310624, EBI-346340;
CC       P09022:Hoxa1 (xeno); NbExp=3; IntAct=EBI-310624, EBI-3957603;
CC       O75340:PDCD6; NbExp=5; IntAct=EBI-310624, EBI-352915;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Melanosome. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome.
CC       Note=Identified by mass spectrometry in melanosome fractions from
CC       stage I to stage IV. Colocalized with CEP55 in the midbody during
CC       cytokinesis. Colocalized with CEP55 at centrosomes of non-dividing
CC       cells.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8WUM4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WUM4-2; Sequence=VSP_044860;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q8WUM4-3; Sequence=VSP_057190, VSP_057191;
CC   -!- PTM: May be phosphorylated on tyrosine residues by activated
CC       PDGFRB. {ECO:0000269|PubMed:20494825}.
CC   -!- SIMILARITY: Contains 1 BRO1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00526}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92092.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF349951; AAK20398.1; -; mRNA.
DR   EMBL; GQ131806; ACS12984.1; -; mRNA.
DR   EMBL; AF151793; AAF08220.1; -; mRNA.
DR   EMBL; BT007367; AAP36031.1; -; mRNA.
DR   EMBL; AC112220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC123901; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020066; AAH20066.1; -; mRNA.
DR   EMBL; BC068454; AAH68454.1; -; mRNA.
DR   EMBL; AK002122; BAA92092.1; ALT_INIT; mRNA.
DR   EMBL; AB037796; BAA92613.1; -; mRNA.
DR   CCDS; CCDS2660.1; -. [Q8WUM4-1]
DR   CCDS; CCDS54561.1; -. [Q8WUM4-2]
DR   RefSeq; NP_001155901.1; NM_001162429.2. [Q8WUM4-2]
DR   RefSeq; NP_001243121.1; NM_001256192.1. [Q8WUM4-3]
DR   RefSeq; NP_037506.2; NM_013374.5. [Q8WUM4-1]
DR   UniGene; Hs.475896; -.
DR   PDB; 2OEV; X-ray; 3.30 A; A=1-698.
DR   PDB; 2OEW; X-ray; 2.55 A; A=1-359.
DR   PDB; 2OEX; X-ray; 2.58 A; A/B=360-702.
DR   PDB; 2OJQ; X-ray; 2.87 A; A=360-702.
DR   PDB; 2R02; X-ray; 2.60 A; A=2-698.
DR   PDB; 2R03; X-ray; 2.59 A; A=2-698.
DR   PDB; 2R05; X-ray; 2.55 A; A=2-698.
DR   PDB; 2XS1; X-ray; 2.30 A; A=1-698.
DR   PDB; 2XS8; X-ray; 2.50 A; A=1-698.
DR   PDB; 2ZNE; X-ray; 2.20 A; C/D=799-812.
DR   PDB; 3C3O; X-ray; 2.15 A; A=1-359.
DR   PDB; 3C3Q; X-ray; 2.10 A; A=1-359.
DR   PDB; 3C3R; X-ray; 2.02 A; A=1-359.
DR   PDB; 3E1R; X-ray; 2.00 A; C=797-809.
DR   PDB; 4JJY; X-ray; 6.50 A; A/B=355-708.
DR   PDBsum; 2OEV; -.
DR   PDBsum; 2OEW; -.
DR   PDBsum; 2OEX; -.
DR   PDBsum; 2OJQ; -.
DR   PDBsum; 2R02; -.
DR   PDBsum; 2R03; -.
DR   PDBsum; 2R05; -.
DR   PDBsum; 2XS1; -.
DR   PDBsum; 2XS8; -.
DR   PDBsum; 2ZNE; -.
DR   PDBsum; 3C3O; -.
DR   PDBsum; 3C3Q; -.
DR   PDBsum; 3C3R; -.
DR   PDBsum; 3E1R; -.
DR   PDBsum; 4JJY; -.
DR   ProteinModelPortal; Q8WUM4; -.
DR   SMR; Q8WUM4; 2-702.
DR   BioGrid; 115332; 75.
DR   DIP; DIP-29327N; -.
DR   IntAct; Q8WUM4; 43.
DR   MINT; MINT-4999333; -.
DR   STRING; 9606.ENSP00000411825; -.
DR   PhosphoSite; Q8WUM4; -.
DR   BioMuta; PDCD6IP; -.
DR   DMDM; 31076831; -.
DR   UCD-2DPAGE; Q8WUM4; -.
DR   MaxQB; Q8WUM4; -.
DR   PaxDb; Q8WUM4; -.
DR   PRIDE; Q8WUM4; -.
DR   DNASU; 10015; -.
DR   Ensembl; ENST00000307296; ENSP00000307387; ENSG00000170248.
DR   Ensembl; ENST00000457054; ENSP00000411825; ENSG00000170248. [Q8WUM4-2]
DR   GeneID; 10015; -.
DR   KEGG; hsa:10015; -.
DR   UCSC; uc003cfx.4; human. [Q8WUM4-1]
DR   CTD; 10015; -.
DR   GeneCards; GC03P033839; -.
DR   H-InvDB; HIX0163463; -.
DR   HGNC; HGNC:8766; PDCD6IP.
DR   HPA; CAB016212; -.
DR   HPA; HPA011905; -.
DR   MIM; 608074; gene.
DR   neXtProt; NX_Q8WUM4; -.
DR   PharmGKB; PA33116; -.
DR   eggNOG; NOG325528; -.
DR   GeneTree; ENSGT00780000121909; -.
DR   HOGENOM; HOG000006938; -.
DR   HOVERGEN; HBG053533; -.
DR   InParanoid; Q8WUM4; -.
DR   KO; K12200; -.
DR   OMA; QVKECYQ; -.
DR   OrthoDB; EOG7V49XV; -.
DR   PhylomeDB; Q8WUM4; -.
DR   TreeFam; TF323502; -.
DR   Reactome; REACT_264618; Uptake and function of anthrax toxins.
DR   Reactome; REACT_6359; Budding and maturation of HIV virion.
DR   ChiTaRS; PDCD6IP; human.
DR   EvolutionaryTrace; Q8WUM4; -.
DR   GeneWiki; PDCD6IP; -.
DR   GenomeRNAi; 10015; -.
DR   NextBio; 37837; -.
DR   PRO; PR:Q8WUM4; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; Q8WUM4; -.
DR   CleanEx; HS_PDCD6IP; -.
DR   ExpressionAtlas; Q8WUM4; baseline and differential.
DR   Genevisible; Q8WUM4; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070971; C:endoplasmic reticulum exit site; IMP:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0001772; C:immunological synapse; IDA:BHF-UCL.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0031871; F:proteinase activated receptor binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0000920; P:cell separation after cytokinesis; IMP:UniProtKB.
DR   GO; GO:1903543; P:positive regulation of exosomal secretion; IMP:UniProtKB.
DR   GO; GO:1903553; P:positive regulation of extracellular exosome assembly; IMP:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0010824; P:regulation of centrosome duplication; IMP:UniProtKB.
DR   GO; GO:1903551; P:regulation of extracellular exosome assembly; IMP:UniProtKB.
DR   GO; GO:0090611; P:ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway; IMP:UniProtKB.
DR   GO; GO:0039702; P:viral budding via host ESCRT complex; IGI:UniProtKB.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   Gene3D; 1.25.40.280; -; 1.
DR   InterPro; IPR025304; ALIX_V_dom.
DR   InterPro; IPR004328; BRO1_dom.
DR   Pfam; PF13949; ALIX_LYPXL_bnd; 1.
DR   Pfam; PF03097; BRO1; 1.
DR   SMART; SM01041; BRO1; 1.
DR   PROSITE; PS51180; BRO1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   Cell cycle; Cell division; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Host-virus interaction; Phosphoprotein;
KW   Polymorphism; Protein transport; Reference proteome; Transport.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:19413330,
FT                                ECO:0000269|PubMed:22223895,
FT                                ECO:0000269|Ref.7}.
FT   CHAIN         2    868       Programmed cell death 6-interacting
FT                                protein.
FT                                /FTId=PRO_0000218891.
FT   DOMAIN        3    392       BRO1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00526}.
FT   REGION      176    868       Interaction with EIAV p9.
FT   REGION      176    503       Interaction with CHMP4A, CHMP4B and
FT                                CHMP4C.
FT   REGION      503    868       Self-association.
FT   REGION      717    720       Interaction with TSG101.
FT   REGION      797    806       Interaction with CEP55.
FT   REGION      864    868       Essential to promote virus budding.
FT   COMPBIAS    717    860       Pro-rich.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:19413330,
FT                                ECO:0000269|PubMed:22223895,
FT                                ECO:0000269|Ref.7}.
FT   MOD_RES     215    215       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES     730    730       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     738    738       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     741    741       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   VAR_SEQ     239    239       K -> KYFYFQ (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044860.
FT   VAR_SEQ     240    271       EVFPVLAAKHCIMQANAEYHQSILAKQQKKFG -> VSYCF
FT                                YKHLLTLHVKYLDFFVYKKQVETYKEI (in isoform
FT                                3). {ECO:0000303|PubMed:19906316}.
FT                                /FTId=VSP_057190.
FT   VAR_SEQ     272    868       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:19906316}.
FT                                /FTId=VSP_057191.
FT   VARIANT       7      7       V -> M (in dbSNP:rs11554560).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_068975.
FT   VARIANT     309    309       A -> T (in dbSNP:rs3792594).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_053017.
FT   VARIANT     378    378       V -> I (in dbSNP:rs3203777).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_053018.
FT   VARIANT     429    429       G -> S (in dbSNP:rs148256302).
FT                                {ECO:0000269|PubMed:22073189}.
FT                                /FTId=VAR_069765.
FT   VARIANT     550    550       N -> S (in dbSNP:rs9813017).
FT                                {ECO:0000269|PubMed:10718198,
FT                                ECO:0000269|PubMed:11683497}.
FT                                /FTId=VAR_053019.
FT   VARIANT     638    638       K -> E (in dbSNP:rs3183982).
FT                                /FTId=VAR_053020.
FT   VARIANT     730    730       S -> L (in dbSNP:rs1127732).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_024381.
FT   MUTAGEN     199    199       F->D: Abolishes interaction with CHMP4B
FT                                and abolishes rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17428861}.
FT   MUTAGEN     212    212       I->D: Abolishes interaction with CHMP4A;
FT                                impairs rescue of PTAP-type L domain-
FT                                deficient HIV-1 p6; inhibits support of
FT                                cytokinesis.
FT                                {ECO:0000269|PubMed:17350572,
FT                                ECO:0000269|PubMed:17853893}.
FT   MUTAGEN     216    216       L->D: Abolishes interaction with CHMP4B
FT                                and abolishes rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17428861}.
FT   MUTAGEN     317    317       F->A: Diminishes rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17428861}.
FT   MUTAGEN     318    318       I->A: Greatly diminishes rescue of PTAP-
FT                                type L domain--deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17428861}.
FT   MUTAGEN     319    319       Y->A: Greatly diminishes rescue of PTAP-
FT                                type L domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17350572,
FT                                ECO:0000269|PubMed:17428861}.
FT   MUTAGEN     319    319       Y->F: No effect on rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17350572,
FT                                ECO:0000269|PubMed:17428861}.
FT   MUTAGEN     495    495       F->D: Impairs rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     498    498       V->D: Reduces interaction with HIV-1 p6
FT                                and EIAV p9; abolishes rescue of PTAP-
FT                                type L domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17277784,
FT                                ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     509    509       V->D: Abolishes interaction with HIV-1
FT                                p6; impairs rescue of PTAP-type L domain-
FT                                deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17277784,
FT                                ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     512    512       C->A: No effect on interaction with HIV-1
FT                                p6; impairs rescue of PTAP-type L domain-
FT                                deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17277784}.
FT   MUTAGEN     676    676       F->D: Abolishes interaction with HIV-1 p6
FT                                and EIAV p9; abolishes rescue of PTAP-
FT                                type L domain-deficient HIV-1 p6; no
FT                                effect on cytokinesis.
FT                                {ECO:0000269|PubMed:17277784,
FT                                ECO:0000269|PubMed:17350572,
FT                                ECO:0000269|PubMed:17853893}.
FT   MUTAGEN     680    680       L->D: Impairs rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     683    683       I->A: No effect on interaction with HIV-1
FT                                p6. {ECO:0000269|PubMed:17277784,
FT                                ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     683    683       I->D: Reduces interaction with HIV-1 p6
FT                                and EIAV p9; abolishes rescue of PTAP-
FT                                type L domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17277784,
FT                                ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     720    720       P->L: Abolishes interaction with TSG101;
FT                                no effect on rescue of PTAP-type L
FT                                domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     757    758       RP->AA: Abolishes interaction with SH3GL1
FT                                and SH3GL2; no effect on rescue of PTAP-
FT                                type L domain-deficient HIV-1 p6.
FT                                {ECO:0000269|PubMed:17350572}.
FT   MUTAGEN     800    802       GPP->AAA: Abolishes interaction with
FT                                CEP55; inhibits support of cytokinesis.
FT                                {ECO:0000269|PubMed:17853893}.
FT   MUTAGEN     801    801       P->A: Diminishes interaction with CEP55.
FT                                {ECO:0000269|PubMed:18948538}.
FT   MUTAGEN     802    802       P->A: Diminishes interaction with CEP55.
FT                                {ECO:0000269|PubMed:18948538}.
FT   MUTAGEN     806    806       Y->A: Abolishes interaction with CEP55.
FT                                {ECO:0000269|PubMed:18948538}.
FT   CONFLICT    580    580       M -> T (in Ref. 8; BAA92092).
FT                                {ECO:0000305}.
FT   HELIX        18     28       {ECO:0000244|PDB:3C3R}.
FT   STRAND       33     35       {ECO:0000244|PDB:3C3R}.
FT   HELIX        39     55       {ECO:0000244|PDB:3C3R}.
FT   HELIX        62     78       {ECO:0000244|PDB:3C3R}.
FT   TURN         79     83       {ECO:0000244|PDB:3C3R}.
FT   TURN         84     86       {ECO:0000244|PDB:2XS1}.
FT   STRAND       93     96       {ECO:0000244|PDB:3C3R}.
FT   STRAND       98    100       {ECO:0000244|PDB:2R05}.
FT   STRAND      104    106       {ECO:0000244|PDB:3C3R}.
FT   STRAND      110    114       {ECO:0000244|PDB:3C3R}.
FT   HELIX       116    136       {ECO:0000244|PDB:3C3R}.
FT   STRAND      140    142       {ECO:0000244|PDB:2OEV}.
FT   HELIX       143    170       {ECO:0000244|PDB:3C3R}.
FT   STRAND      171    173       {ECO:0000244|PDB:2OEV}.
FT   TURN        177    179       {ECO:0000244|PDB:3C3R}.
FT   HELIX       181    205       {ECO:0000244|PDB:3C3R}.
FT   HELIX       210    231       {ECO:0000244|PDB:3C3R}.
FT   HELIX       241    266       {ECO:0000244|PDB:3C3R}.
FT   HELIX       270    290       {ECO:0000244|PDB:3C3R}.
FT   TURN        292    294       {ECO:0000244|PDB:3C3R}.
FT   HELIX       298    317       {ECO:0000244|PDB:3C3R}.
FT   HELIX       326    328       {ECO:0000244|PDB:3C3R}.
FT   STRAND      348    350       {ECO:0000244|PDB:3C3R}.
FT   TURN        354    357       {ECO:0000244|PDB:3C3Q}.
FT   HELIX       361    398       {ECO:0000244|PDB:2XS1}.
FT   TURN        399    402       {ECO:0000244|PDB:2XS1}.
FT   HELIX       403    406       {ECO:0000244|PDB:2XS1}.
FT   STRAND      408    412       {ECO:0000244|PDB:2R05}.
FT   HELIX       415    426       {ECO:0000244|PDB:2XS1}.
FT   TURN        427    429       {ECO:0000244|PDB:2XS1}.
FT   HELIX       430    471       {ECO:0000244|PDB:2XS1}.
FT   TURN        473    475       {ECO:0000244|PDB:2XS1}.
FT   HELIX       481    514       {ECO:0000244|PDB:2XS1}.
FT   HELIX       517    523       {ECO:0000244|PDB:2XS1}.
FT   HELIX       527    532       {ECO:0000244|PDB:2XS1}.
FT   HELIX       541    543       {ECO:0000244|PDB:2XS1}.
FT   HELIX       547    575       {ECO:0000244|PDB:2XS1}.
FT   HELIX       581    590       {ECO:0000244|PDB:2XS1}.
FT   STRAND      591    593       {ECO:0000244|PDB:2R05}.
FT   HELIX       596    639       {ECO:0000244|PDB:2XS1}.
FT   HELIX       644    697       {ECO:0000244|PDB:2XS1}.
FT   STRAND      802    805       {ECO:0000244|PDB:3E1R}.
FT   TURN        810    812       {ECO:0000244|PDB:2ZNE}.
SQ   SEQUENCE   868 AA;  96023 MW;  573588D1F612EC93 CRC64;
     MATFISVQLK KTSEVDLAKP LVKFIQQTYP SGGEEQAQYC RAAEELSKLR RAAVGRPLDK
     HEGALETLLR YYDQICSIEP KFPFSENQIC LTFTWKDAFD KGSLFGGSVK LALASLGYEK
     SCVLFNCAAL ASQIAAEQNL DNDEGLKIAA KHYQFASGAF LHIKETVLSA LSREPTVDIS
     PDTVGTLSLI MLAQAQEVFF LKATRDKMKD AIIAKLANQA ADYFGDAFKQ CQYKDTLPKE
     VFPVLAAKHC IMQANAEYHQ SILAKQQKKF GEEIARLQHA AELIKTVASR YDEYVNVKDF
     SDKINRALAA AKKDNDFIYH DRVPDLKDLD PIGKATLVKS TPVNVPISQK FTDLFEKMVP
     VSVQQSLAAY NQRKADLVNR SIAQMREATT LANGVLASLN LPAAIEDVSG DTVPQSILTK
     SRSVIEQGGI QTVDQLIKEL PELLQRNREI LDESLRLLDE EEATDNDLRA KFKERWQRTP
     SNELYKPLRA EGTNFRTVLD KAVQADGQVK ECYQSHRDTI VLLCKPEPEL NAAIPSANPA
     KTMQGSEVVN VLKSLLSNLD EVKKEREGLE NDLKSVNFDM TSKFLTALAQ DGVINEEALS
     VTELDRVYGG LTTKVQESLK KQEGLLKNIQ VSHQEFSKMK QSNNEANLRE EVLKNLATAY
     DNFVELVANL KEGTKFYNEL TEILVRFQNK CSDIVFARKT ERDELLKDLQ QSIAREPSAP
     SIPTPAYQSS PAGGHAPTPP TPAPRTMPPT KPQPPARPPP PVLPANRAPS ATAPSPVGAG
     TAAPAPSQTP GSAPPPQAQG PPYPTYPGYP GYCQMPMPMG YNPYAYGQYN MPYPPVYHQS
     PGQAPYPGPQ QPSYPFPQPP QQSYYPQQ
//
